Dioxolocoumarins: Bridging chemistry and pharmacology with multifunctional therapeutics

Dioxolocoumarin compounds (DCCs) are interesting bioactive molecules that could be used in medicine. They are made up of a coumarin scaffold and a 1,3-dioxolane ring. This review brings together the latest research on both naturally occurring and man-made DCCs, focusing on their wide range of medical benefits and the creative ways they are made to make them work better. DCCs have demonstrated significant activity as anticancer agents, particularly in leukemia and glioma cell lines, owing to their ability to modulate cellular growth pathways and induce apoptosis. In addition, their ability to fight oxidative stress and inflammation makes them a beneficial choice for treating oxidative stress-related diseases. DCCs have strong anticancer properties and have also been shown to be effective against microbial and parasitic pathogens, such as Staphylococcus aureus, Escherichia coli, and Leishmania amazonensis. The part of xanthine oxidase inhibitors shows how DCCs could be used to treat high uric acid and gout. Studies have also demonstrated the anticoagulant, antiviral, and neuroprotective properties of DCCs. This means they can be used to treat a wider range of diseases, including cardiovascular, infectious, and neurodegenerative diseases. Different ways of making DCCs have changed over time, using ring-closing reactions and targeted modifications to make them more biologically active and specific. Structural variations, including substitutions on the coumarin core, have enhanced their pharmacokinetics and potency against specific targets. This review also looks at how DCCs work, which can help us understand the relationships between structure and activity and guide future drug development. DCCs, with their diverse therapeutic potential, present a promising platform for next-generation pharmaceutical development, serving as a bridge between natural product research and innovative drug discovery